

<!-- page 1 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2017'02'14
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 14.02.2017
1A
w;s úfYI
wxl 2006$15 - 2017 fmnrjdß ui 14 jeks w`.yrejdod - 2017'02'14
No. 2006/15  -  TUESDAY,  FEBRUARY  14,  2017
EXTRAORDINARY
Y%S ,xld m%cd;dka;%sl iudcjd§ ckrcfha .eiÜ m;%h
The Gazette of the Democratic Socialist Republic of Sri Lanka
(Published by Authority)
PART I : SECTION (I) — GENERAL
Government  Notifications
This Gazette Extraordinary can be downloaded from www.documents.gov.lk
                  
       
              
               
            
        
                  
     
         
             
         
               
            
               
               
            
               
        
                 
        
              
               
            
         
                  
CONVENTION   AGAINST  DOPING  IN   SPORT  ACT,   No.  33   OF  2013
REGULATIONS made by the Minister of  Sports under Section 34 read with Section 3 of the Convention against Doping in
Sport Act, No. 33 of 2013.
DAYASIRI J AY ASEKARE,
Minister of Sports.
Colombo,
14th December, 2016.
Regulations
1. These regulations may be cited as the Anti-Doping (Prohibited List) Regulations  No. 02 of 2016.
2. These regulations shall be deemed to have come into  operation on  1
st, January 2017.
THE   WORLD   ANTI-DOPING   CODE
THE   2017 P ROHIBITED LIST
INTERNATIONAL - STANDARD
The Official text of the Prohibited List shall be maintained by WADA and shall be published in English and French.
In the event of any conflict between the English and French versions,  the English  version shall prevail.
This List shall come into effect on 01 st  January 2017.
The 2017 prohibited List
30th September 2016

<!-- page 2 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2017'02'14
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 14.02.2017
2A
THE  WORLD    ANTI-DOPING    CODE
INTERNATIONAL STANDARD
PROHIBITED    LIST  JANUARY 2017
This List shall come into effect on 01 st January 2017
IN ACCORDANCE WITH ARTICLE  4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED
SUBSTANCES SHALL  BE CONSIDERED  AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES
S1, S2, S4.4,  S4.5, S6.A, AND PROHIBITED METHODS  M1, M2 AND M3.
SUBSTANCES    AND    METHODS    PROHIBITED    AT    ALL   TIMES
(IN-AND  OUT-OF-COMPETITION)
PROHIBITED    SUBSTANCES
S0. NON-APPROVED   SUBSTANCES
Any pharmacological substance which is not addressed  by any of the subsequent sections of the List and with no current
approval by any governmental  regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or
clinical developement or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all
times.
S1.   ANABOLIC   AGENTS
Anabolic agents are prohibited.
1. ANABOLIC  ANDROGENIC  STEROIDS (AAS)
a. Exogenous*  AAS,  including:
1- Androstenediol 
(5-androst-1-ene-317-diol); 1-Androstenedione (5-androst-1-ene-3,17-dione); 1-Testosterone [-hydroxy-
5-androst-1-en-3-one]: 4-Hydroxytestosterone[4, -dihydroxyandrost-4-en-3-one] Bolandiol  (estr -4-ene-3 17-diol);
Bolasterone; Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17-ol); Dehydrochlormethyltestosterone
(4-chloro- -hydroxy- -methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone  ( -methyl-5 -androst-2-en- -ol);
Drostanolone  ; Ethylestrenol  (19-norpregna-4-en- -ol); Fluoxymesterone;  Formebolone; Furazabol  ( -
methyl[1,2,5]oxadiazolo[3',4':2,3]-5-androstan--ol); Gestrinone; Mestanolone, Mesterolone, Metandienone; (-hydroxy-17-
methylandrosta-1,4-dien-3-one); Metenolone; Methandriol; Methasterone  ( -hydroxy-2 ,17-dimethyl-5 -androstan-3-one);
Methyldienolone (-hydroxy-17-methylestra-4,9-dien-3-one);  Methyl-1-testosterone (-hydroxy-17,methyl-5-androst-1-en-3-
one); Methylnortestosterone  (-hydroxy-17-methylestr-4-en-3 one) ; Methyltestosterone; Metribolone (methyltrienolone,-hydroxy-
17-methylestra-4,9,11-trien-3-one); Mibolerone;  Norboletone  Norclostebol; Norethandrolone; Oxabolone; Oxandrolone ;
Oxymesterone; Oxymetholone; Prostanozol  ( -[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 -androstane); Quinbolone;
Stanozolol; Stenbolone; Tetrahydrogestrinone (-hydroxy-18a-homo-19-nor-17-pregna-4,9,11-trien-3-one); Trenbolone  (-hydroxyestr-
4,9,11-trien-3-one); and  other substances with a similar chemical structure or similar biological effect (s).
b. Endogenous** AAS  when administered exogenously :
19-Norandrostenediol (estr-4-ene-3, 17-diol);19-Norandrostenedione (estr-4-ene-3, 17-dione);
Androstenediol (androst-5-ene-3 17-diol);  Androstenedione, (androst-4-ene-3,17-dione); Boldenone; Boldione (androsta-1, 4-
diene-3, 17-dione);  Dihydrotestosterone  (-hydroxy-5 -androstan-3-one); Nandrolone (19-nortestosterone);  Prasterone
(dehydroepiandrosterone, DHEA,3-hydroxyandrost-5-en-17-one);  Testosterone; and their metabolites and  isomers, including but
not limited to:
3-Hydroxy-5 -androstan-17-one; 5-Androst-2-ene- one; -Androstane-3 ,17 -diol;  -Androstane-3 ,17-diol;
5-Androstane-,-diol; 5  - Androstane - 3 
, 17  - diol ; 5 -Androstane-.-diol;- 7 -Hydroxy-DHEA; 7 -Hydroxy-
DHEA; 4-Androstenediol (androst-4-ene- ,-diol); 5-androstenedione (androst-5-ene-3, 17-dione) ; 7-keto-DHEA ; 19-
Norandrosterone ; 19-Noretiocholanolone. Androst-4-ene-3 ,17-diol;Androst-4-ene-3 ,17-diol;Androst-4-ene-3 ,17-diol;
Androst-5-ene-3 ,17 -diol;Androst-5-ene-3 ,17 -diol;Androst-5-ene-3 ,17 -diol;Androsteron: Epi-dihydrotestoterone
Epitestosterone:Etiocholanolone.

<!-- page 3 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2017'02'14
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 14.02.2017
3A
 2. OTHER   ANABOLIC   AGENTS
Including, but not limited to:
Clenbuterol, selective androgen receptor modulators  (SARMs; e.g. andarine and ostarine), Tibolone, Zeranol
and Zilpaterol.
For purposes of this section:
* “exogenous” refers to a substance which is not ordinarily  produced by the body naturally.
** “endogenous” refers to a substance which is  ordinarily  produced by the body naturally.
S2. PEPTIDE  HORMONES,   GROWTH     FACTORS,   RELATED    SUBSTANCES   AND   MIMETICS
The following substances, and other substances with similar chemical structure or similar  biological effect(s), are
prohibited:
1. Erythropoietin - Receptor agonists :
1.1 Erythropoiesis-Stimulating Agents (ESAs)  including e.g. Darbepoietin (dEPO);  Erythropoietins (EPO) ;
EPO-Fc; EPO mimetic peptides  (EMP), e.g.  CNTO 530 and peginesatide; GATA inhibitors, e. g. K-
11706; Methoxy polyethylene glycol-epoetin beta  (CERA). Transforming Growth Factor - 
(TGF-)
inhibitors, e. g. sotatercept, luspatercept ;
1.2 Non - erythropoietic EPO - Receptor agonists,  e.g. ARA - 290 ; Asialo EPO; Carbamylated EPO.
2. Hypoxia - inducible factor (HIF) stabilizers, e.g. cobalt molidustat and roxadustat [FG-4592]; and HIF activators,
e.g. argon, xenon;
3. Chorionic Gonadotrophin (CG) and Luteinizing  Hormone (LH) and their releasing factors, e.g. buserelin,
gonadorelin and leuprorelin, in males;
4. Corticotrophins and their releasing factors, e. g. corticorelin ;
5. Growth Hormone  (GH) and its releasing factors including; Growth Hormone Releasing Hormone  (GHRH)
and its analogues , e.g. CJC-1295, sermorelin  and tesamorelin;  Growth Hormone Secretagogues  (GHS),
e.g. ghrelin and ghrelin mimetics,  e.g. anamorelin and ipamorelin;  GH - Releasing Peptides  (GHRPs), e.g.
alexamorelin,  GHRP - 6, hexarelin  and pralmorelin (GHRP - 2).
Additional prohibited growth factors ;
Fibroblast Growth Factors  (FGFs); Hepatocyte Growth Factor  (HGF); Insulin-like Growth Factor - 1
(IGF-1)  and its analogues; Mechano Growth Factors  (MGFs); Platelet-Derived Growth Factor  (PDGF);
Vascular-Endothelial Growth Factor (VEGF) and any other growth factor affecting muscle, tendon or ligament
protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity, or fibre type switching.
S3. BETA - 2 AGONISTS
All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited.
Including, but not limited to :
Fenoterol ; Formoterol ; Higenamine ; Indacaterol ; Olodaterol ; Procaterol ; Reproterol ; Salbutamol ; Salmeterol ;
Terbutaline ; Vilanterol
Except :
* Inhaled salbutamol : maximum 1600 micrograms over 24 hours, not to exceed 800 micrograms every 12 hours;
* Inhaled formoterol : maximum delivered dose of 54  micrograms over 24 hours ;
* Inhaled salmeterol  : maximum 200 micrograms over 24 hours

<!-- page 4 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2017'02'14
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 14.02.2017
4A
The presence in urine of salbutamol in excess of 1000 ng/ml or formoterol in excess of 40ng/ml is presumed not to be an
intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete
proves, through  a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the
therapeutic inhaled dose (by inhalation) up to the maximum indicated above.
S4.   HORMONE   AND   METABOLIC   MODULATORS
The following hormone and metabolic modulators are prohibited:
1. Aromatase inhibitors including, but not limited to: 4-Androstene-3, 6, 17 trione (6-oxo) ;
Aminoglutethimide; Anastrozole; Androsta - 1,4,6,-triene-3,17-dione  (androstatrienedione);
Androsta-3,5-diene-7, 17 dione  (arimistane); Exemestane; Formestane; Letrozole;  Testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to : Raloxifene; Tamoxifen ;  Toremifene.
3. Other anti-estrogenic substances  including, but not limited to: Clomiphene; Cyclofenil and Fulvestrant .
4. Agents modifying myostatin function (s)  including, but not limited, to : myostatin inhibitors .
5. Metabolic  modulators:
5.1 Activators of the AMP-activated protein kinase  (AMPK) e.g. AICAR; and Peroxisome Proliferator
Activated Receptor  
(PPAR)  agonists, e.g. GW 1516;
5.2 Insulins and Insulin - Mimetics
5.3 Meldonium;
5.4 Trimetazidine.
S5. DIURETICS    AND   MASKING    AGENTS
The following  diuretics, and masking agents  are prohibited, as are other substances with a similar chemical structure
or similar biological effect (s)
Including, but not limited to:
* Desmopressin; probenecid; plasma expanders , e.g. glycerol and intravenous administration of albumin,
dextran,  hydroxyethyl starch  and mannitol.
* Acetazolamide; amiloride;  bumetanide; canrenone; chlortalidone;  etacrynic acid; furosemide;
indapamide; metolazone; spironolactone; thiazides,  e.g.  bendroflumethiazide, chlorothiazide and
hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.
Except:
Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors
(e.g. dorzolamide, brinzolamide) ;
Local administration of felypressin in dental anaesthesia.

<!-- page 5 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2017'02'14
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 14.02.2017
5A
The detection in an Athlete’s Sample at all times or In -Competition, as applicable, of any quantity of the following substances
subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction
with a diuretic or masking agent, will be considered as an Adverse Analytical Finding  (AAF) unless the Athlete has an
approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking
agent.
PROHIBITED   METHODS
M1.  MANIPULATION    OF    BLOOD   AND   BLOOD    COMPONENTS
The following  are prohibited:
1. The administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous
blood, or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of  oxygen.
Including, but not limited to:
Perfluorochemicals; efaproxiral (RSR 13) and modified  haemoglobin products, e.g. haemoglobin-based blood
substitutes and microencapsulated haemoglobin  products, excluding supplemental oxygen by inhalation.
3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.
M2.  CHEMICAL    AND   PHYSICAL    MANI PULATION
The following are prohibited:
1. Tampering, or Attempting to Tamper, to alter the integrity and  validity of Samples collected during Doping Control.
Including, but not limited to:
Urine substitution and/or adulteration, e.g. proteases.
2. Intravenous infusions and /or injections of more than 50ml  per 6 hour period except for those legitimately received
in the course of hospital admissions, surgical procedures or clinical investigations.
M3.  GENE    DOPING
The following with the potential to enhance sport performance, are prohibited:
1. The transfer of ploymers of nucleic acids  or nucleic acid analogues;
2. The use of normal or genetically modified cells.
SUBSTANCES   AND    METHODS
PROHIBITED IN- COMPETITION
IN ADDITION TO  THE  CATEGORIES  S0 TO  S5  AND M1  TO  M3  DEFINED  ABOVE,
THE   FOLLOWING  CATEGORIES  ARE  PROHIBITED  IN - COMPETITION:
PROHIBITED    SUBSTANCES
S6. STIMULANTS
All stimulants, including all optical isomers, e.g. d- and l- where relevant, are prohibited.
Stimulants include:

<!-- page 6 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2017'02'14
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 14.02.2017
6A
(a) Non- Specified Stimulants:
Adrafinil; Amfepramone; Amfetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex;
Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4- phenylpiracetam
(carphedon)] ; Furfenorex; Lisdexamfetamine; Mefenorex; Mephentermine; Mesocarb; Metamfetamine ( d-) ; p-
Methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine and Prolintane.
A stimulant not expressly  listed in this section is a Specified Substance.
b. Specified Stimulants.
Including, but not limited to:
4-Methylhexan-2-amine (methylhexaneamine); Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone,
methedrone, and   -pyrrolidinovalerophenone; Dimethylamphetamine; Ephedrine ***; Epinephrine**** (adrenaline);
Etamivan; Etilamfetamine;  Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamfetamine
(parahydroxyamphetamine); Isometheptene; Levmetamfetamine;  Meclofenoxate; Methylenedioxymethamphetamine;
Methylephedrine***;  Methylphenidate; Nikethamide, Norfenefrine; Octopamine; Oxilofrine (methylsynephrine)
Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine;
Pseudoephedrine*****; Selegiline; Sibutramine; Strychnine; Tenamfetamine (methylenedioxyamphetamine),
Tuaminoheptane;  and other substances with a similar chemical structure or similar biological effect(s).
Except:
* Clonidine
* Imidazole derivatives for topical/ophthalmic use and those stimulants included in the 2017 monitoring Program*.
* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine; These substances
are included in the 2017 monitoring Program, and are not considered Prohibited Substances .
** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.
*** Ephedrine and methylephedrine:  Prohibited when the concentration of either in urine is greater than 10  micrograms
per milliliter.
**** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration
with local anaesthetic agents.
***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter.
S7. NARCOTICS
Prohibited:
Buprenorphine ; Dextromoramide ;  Diamorphine (heroin); Fentanyl  and its derivatives ; Hydromorphone ;
Methadone; Morphine; Nicomorphine- Oxycodone ; Oxymorphone; Pentazocine;  Pethidine.
S8. CANNABINOIDS
Prohibited:
* Natural, e.g. cannabis, hashish and marijuana, or synthetic   9 - tetrahydrocannabinol (THC)
   * Cannabimimetics, e.g. “Spice”, JWH-018, JWH-073, HU-210.
S9. GLUCOCORTICOIDS
All glucocorticoids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

<!-- page 7 -->

I fldgi ( ^ I& fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜ m;%h - 2017'02'14
PART I : SEC. (I) - GAZETTE EXTRAORDINARY OF THE  DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA - 14.02.2017
7A
SUBSTANCES   PROHIBITED   IN ; PARTICULAR     SPORTS
P1. ALCOHOL
Alcohol (ethanol) is prohibited  In-Competition only, in the following sports, Detection will be conducted by analysis
of breath and /or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10g/L.
 * Air Sports (FAI) * Powerboating (UIM)
* Archery (WA)
* Automobile (FIA)
P2. BETA - BLOCKERS
Beta-blockers are prohibited  In-Competition only, in the following sports, and also prohibited Out-of-Competition where
indicated.
Archery (WA)*
Automobile (FIA)
Billiards (all disciplines) (WCBS)
Darts (WDF)
Golf (IGF)
Shooting (ISSF, IPC)*
Skiing/Snowboarding (FIS) in ski Jumping, Freestyle aerials/halfpipe and snowboard halfpipe/big air.
Underwater sports (CMAS) in constant-weight apnoea with or without fins, dynamic apnoea with and without
fins, free immersion apnoea, Jump Blue apnoea, spearfishing, static apnoea, target shooting and variable weight
apnoea.
* Also prohibited Out-of-Competition
Including, but not limited to :
Acebutolol; Alprenolol; Atenolol; Betaxolol; Bisoprolol; Bunolol; Carteolol; Carvedilol; Celiprolol; Esmolol; Labetalol;
Levobunolol; Metipranolol; Metoprolol; Nadolol; Oxprenolol; Pindolol; Propranolol; Sotalol  Timolol.
MONITORING   PROGRAMME
The following were added to establish patterns of use :
* Codeine
* Concurrent use of multiple beta-2-agonists
01-82
PRINTED AT THE DEPARTMENT OF GOVERNMENT PRINTING, SRI LANKA.